InnoCan Pharma Corporation (“InnoCan” or the “Company”) (CSE:INNO) announced today that it has signed an agreement with Biogenesis Inc.( “Biogenesis”) of NJ, USA to manufacture its cannabidiol (CBD) based cosmetic and OTC topical products for the US market.


Biogenesis will manufacture InnoCan’s CBD OTC topical and cosmetic products in accordance with Innocan’s formulations as developed by Innocan’s R&D team led by Nir Avram, a senior pharmaceutical scientist with more than 30 years’ industry experience.

Biogenesis will be responsible for procurement of raw (other than CBD inputs, which are the responsibility of InnoCan to provide to Supplier) according to InnoCan specs, manufacturing, and filling and packaging services in their state of the art facilities in New Jersey.

Iris Bincovich, CEO of InnoCan, said, “We have now reached our final milestone to prepare for full retail commercialization of InnoCan products in 2020. Our intention was for InnoCan to enter the world’s largest CBD cosmetic and OTC topical markets and this agreement, along with our recent manufacturing agreement in the EU, positions InnoCan to be well positioned to profit in the rapidly growing consumer market for CBD enhanced products. Biogenesis is a leading manufacturer and provides InnoCan with the necessary expertise, experience and reputation to produce its products for the US market. Initial production will be focused on small lot sizes to build a US domestic distributor and consumer presence. We are targeting commencement of manufacturing in the United Stated for [March 2020].”

About InnoCan Pharma Corporation

InnoCan Pharma brings pharmacological rigour to the burgeoning CBD marketplace. The founders and officers of InnoCan all have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally. InnoCan’s business has three distinct operating segments relating to the incorporation in products of CBD in their formulation: (i) research, development, marketing, distribution and sales of InnoCan-branded OTC pharmaceutical products; (ii) research and development of non-pharmaceutical products for third parties in exchange for fees and/or royalties; and (iii) research and development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales.

About Biogenesis Inc.

Biogenesis is a full-service FDA registered and certified GMP facility, contract manufacturer of skin care, over the counter (OTC) preparations and color cosmetic (makeup) products.

Biogenesis executes operations through a state of the art web-based custom manufacturing management system which tracks projects from receiving customer components, raw material inventory, QC control, and formulation all the way through shipment of manufactured customer products.

For further information, please contact:

For InnoCan Pharma Corporation
Iris Bincovich, CEO

For Investor Relations
Proconsul Capital Ltd.
Andreas Curkovic



US Election 2020 and Cannabis

Investing in cannabis? Read what experts have to say about cannabis and the US Election!

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email or for information on the class action.

Keep reading... Show less

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less